Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH ... San Francisco (UCSF). Patients often have comorbidities that make it important to consider ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

UCSF Health’s Lung Transplant program has been awarded INTERLINK’s 2025 Chairman’s Award for Transplant Excellence as the top-performing lung transplant program in the nation. The UCSF program, which ...

"Raising awareness of pulmonary hypertension associated with interstitial lung disease (or PH-ILD) alongside our advocacy partners is a critical component of our collective effort to ensure ...

"I'm Aware That I'm Rare: the phaware® podcast," delving into the fast-evolving world of Pulmonary Hypertension associated with ...

Mar. 27, 2025 — A research team has investigated structural changes in kidneys of patients with hypertension and type 2 diabetes. The results show that high blood pressure can lead to ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics ...

1 Division of Pulmonary and Critical Care Medicine ... CA 94143-0111, USA; mark.eisner{at}ucsf.edu Background COPD is a major cause of disability, but little is known about how disability develops in ...